

1 **Title:** The Individual and Social Determinants of COVID-19 in Ontario, Canada: A
2 Population-Wide Study

3
4 **Authors:** Maria E. Sundaram, PhD¹, Andrew Calzavara, MS¹, Sharmistha Mishra*, MD,
5 PhD^{2,3,4,5}, Rafal Kustra, PhD^{6,7}, Adrienne K. Chan, MD^{2,3,6,8}, Mackenzie A. Hamilton,
6 BS^{1,6}, Mohamed Djebli, BS^{1,6}, Laura C. Rosella, PhD^{1,6}, Tristan Watson, MPH^{1,6}, Hong
7 Chen, PhD^{1,6,9}, Branson Chen, MSc¹, Stefan D. Baral*, MD¹⁰, Jeffrey C. Kwong*,
8 MD^{1,6,9,11,12}

9
10 **Author affiliations:**

11 ¹ ICES, Toronto, ON

12 ² Department of Medicine, University of Toronto, Toronto, ON

13 ³ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto,
14 ON

15 ⁴ Institute of Medical Science, University of Toronto, Toronto, ON

16 ⁵ MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St.
17 Michael's Hospital, Unity Health Toronto

18 ⁶ Dalla Lana School of Public Health, University of Toronto, Toronto, ON

19 ⁷ Department of Statistical Sciences, University of Toronto, Toronto, ON

20 ⁸ Sunnybrook Health Sciences Centre, Toronto, ON

21 ⁹ Public Health Ontario, Toronto, ON

22 ¹⁰ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
23 Baltimore, MN

24 ¹¹ Department of Family and Community Medicine, University of Toronto, Toronto, ON

25 ¹² University Health Network, Toronto, ON

26 * Equal contribution

27

28 **Corresponding author:** Jeff Kwong, MD

29

30

31 **Word count:** 2989 (not counting abstract, figures, & tables)

32

33 **Abstract word count:** 347

34

35 **Key Points word count:** 101

36 **Key Points**

37 Question: What are the social determinants of health that contextualize individual-level
38 risks for coronavirus disease 2019 (COVID-19), and how do selection biases affect our
39 understanding of these risks?

40

41 Findings: In this province-wide observational study of 14.7 million Canadians, social
42 determinants related to housing, education, and recent immigration were associated
43 with increased COVID-19 risks, with little evidence of selection bias. Individual factors,
44 such as underlying health conditions, were more prone to selection bias using certain
45 analytic approaches.

46

47 Meaning: Social determinants of health appear to drive COVID-19 incidence in Ontario,
48 Canada. Interventions aiming to prevent COVID-19 transmission should address these
49 empiric structural risks.

50 **Abstract**

51 Importance: Optimizing the public health response to reduce coronavirus disease 2019
52 (COVID-19) burden necessitates characterizing population-level heterogeneity of
53 COVID-19 risks. However, heterogeneity in severe acute respiratory syndrome
54 coronavirus 2 (SARS-CoV-2) testing may introduce biased estimates depending on
55 analytic design.

56
57 Objective: Characterizing individual, environmental, and social determinants of SARS-
58 CoV-2 testing and COVID-19 diagnosis.

59
60 Design: We conducted cross-sectional analyses among 14.7 million people comparing
61 individual, environmental, and social determinants among individuals who were tested
62 versus not yet tested. Among those diagnosed, we used three analytic designs to
63 compare predictors of: 1) individuals testing positive versus negative; 2) symptomatic
64 individuals testing positive versus negative; and 3) individuals testing positive versus
65 individuals not testing positive (i.e. testing negative or not being tested). Analyses
66 included tests conducted between March 1 and June 20, 2020.

67
68 Setting: Ontario, Canada.

69
70 Participants: All individuals with ≥ 1 healthcare system contact since March 2012,
71 excluding individuals deceased before, or born after, March 1, 2020, or residing in a
72 long-term care facility.

73

74 Exposures: Individual-level characteristics (age, sex, underlying health conditions, prior
75 healthcare use), area-based environmental (air pollution) exposures, and area-based
76 social determinants of health (income, education, housing, marital status, race/ethnicity,
77 and recent immigration).

78

79 Main Outcomes and Measures: Odds of SARS-CoV-2 test, and of COVID-19 diagnosis.

80

81 Results: Of a total of 14,695,579 individuals, 758,691 had been tested, of whom 25,030
82 (3.3%) tested positive. The further the odds of testing from the null, the more variability
83 observed in the odds of diagnosis across analytic design, particularly among individual
84 factors. There was less variability in testing by social determinants across analytic
85 design. Residing in areas with highest household density (adjusted odds ratio: 2.08;
86 95%CI: 1.95-1.21), lowest educational attainment (adjusted odds ratio: 1.52; 95%CI:
87 1.44-1.60), and highest proportion of recent immigrants (adjusted odds ratio: 1.12;
88 95%CI: 1.07-1.16) were consistently related to increased odds of COVID-19 across
89 analytic designs.

90

91 Conclusions and Relevance: Where testing is limited, risk factors may be better
92 estimated using population comparators rather than test-negative comparators.
93 Optimizing COVID-19 responses necessitates investment and sufficient coverage of
94 structural interventions tailored to heterogeneity in social determinants of risk, including
95 household crowding and systemic racism.

96

97 **Introduction**

98 The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
99 virus causing coronavirus disease 2019 (COVID-19), has resulted in a pandemic with
100 heterogeneity in exposure and transmission risks.¹⁻⁴ There has been greater focus on
101 characterizing individual determinants of COVID-19, such as age,^{2,5} sex,^{6,7} and
102 underlying health conditions,^{2,8} than on social determinants of health.⁹

103

104 Heterogeneity in social determinants of COVID-19 may exist at the individual and
105 network levels (for example, by housing density¹⁰⁻¹²). In addition, social determinants
106 including barriers to healthcare, systemic racism, and xenophobia have been implicated
107 in COVID-19 risk.^{13,14} Environmental determinants such as ambient air pollution may
108 also play a role, as existing evidence indicates that higher ambient air pollution
109 increases risk for infection with other respiratory viruses.¹⁵ While previous studies
110 suggest that air pollution may be biologically related to COVID-19,¹⁶ including severe
111 COVID-19,^{17,18} it may also play a role in COVID-19 risk by operating within the context
112 of low-quality housing and environmental racism.^{19,20}

113

114 Using observational data to identify determinants of COVID-19 relies on SARS-CoV-2
115 testing, which is not equally distributed.⁷ Differential testing introduces the potential for
116 selection biases,^{21,22} including collider bias.²² Collider bias may be introduced into
117 observational studies if the determinants under investigation are related to both COVID-
118 19 and the likelihood of testing.²²⁻²⁴

119

120 Thus, to identify heterogeneity across potential determinants of COVID-19, we
121 examined individual, environmental, and social determinants associated with SARS-
122 CoV-2 testing and diagnoses among 14.7 million individuals in Ontario, Canada. We
123 compared three analytic approaches to examine the role of selection biases.²²

124

125 **Methods**

126 Study population, setting, and design

127 We conducted an observational study using population-based laboratory and health
128 administrative databases from Ontario, Canada. Ontario has a single-payer health
129 system that provides universal access to hospital and physician services²⁵ and
130 laboratory testing.²⁶ We used data from individuals tested between March 1 and June
131 20, 2020 to identify determinants associated with testing, and then used three analytic
132 designs to identify determinants associated with laboratory-confirmed diagnosis of
133 COVID-19.

134

135 Data sources, linkages, and inclusion criteria

136 We linked individual-level SARS-CoV-2 testing data from the Ontario Laboratories
137 Information System (OLIS) to relevant health-related datasets containing demographic,
138 healthcare use, and area-level information (**eTable 1**). These datasets were linked
139 using unique encoded identifiers and analyzed at ICES, a not-for-profit research
140 institute in Ontario.²⁷

141

142 OLIS captured approximately 88% of all laboratory-confirmed COVID-19 cases reported
143 by the province during the study period. OLIS records included specimen collection date,
144 results, and a text field for symptoms completed by healthcare providers at the time of
145 sampling. We obtained individual- and area-level demographic and environmental
146 information from the Registered Persons Database; the Canadian Institute for Health
147 Information's Discharge Abstract Database, Same Day Surgery Database, and National
148 Ambulatory Care Reporting System; the Ontario Health Insurance Program; the Ontario
149 Mental Health Reporting System; the Ontario Population Health and Environment
150 Cohort; and the 2016 Canadian Census.²⁸ Further details are available below and in
151 **eTable 1**.

152

153 To assess community transmission risks, we included individuals who were tested for
154 SARS-CoV-2 by polymerase chain reaction tests and were not residing in a long-term
155 care facility as of March 1, 2020 (**Figure 1**). For individuals with more than one test in
156 OLIS, we used the first positive or indeterminate test, or the first negative test if all tests
157 during the study period were negative. Never-tested individuals during the study period
158 were included if they were not recorded as deceased before, or born after, March 1,
159 2020, and were not residing in a long-term care facility. A diagram of individuals
160 included and excluded is shown in **Figure 1**.

161

162 *Selection and definition of potential determinants of COVID-19 diagnoses*

163 Individual-level determinants included sex, age group, underlying health conditions, and
164 prior healthcare use (**eTable 1**). Underlying health conditions were selected as: a)

165 health conditions identified in the literature as associated with COVID-19 severity^{2,29-32}
166 or associated with symptoms similar to those caused by COVID-19, because severity
167 and symptoms may lead to differential testing and thus, selection bias;³³⁻³⁸ or b) health
168 conditions such as dementia that increase the need for personal care support, thereby
169 reflecting network-level contact patterns that intersect with occupational risks among
170 essential care providers.^{39,40}

171
172 Healthcare use was hypothesized to increase access to testing, and/or signal a marker
173 for comorbidities, and was measured by number of hospital admissions in the past 3
174 years; number of outpatient physician visits in the past year; and influenza vaccination
175 in the 2019-2020 season. We also included ACG[®] System⁴¹ Aggregated Diagnostic
176 Groups (ADGs)⁴² as a composite measure of comorbidities.

177
178 Environmental determinants included fine particulate matter (PM_{2.5}) using satellite-
179 derived estimates⁴³ and land-use regression model for NO₂,⁴⁴ at the postal-code level.

180
181 Social determinants were conceptualized as area-based variables that may signal
182 contact rates within and/or outside households [household density, uncoupled (for
183 example, not married) status],^{45,46} socio-economic barriers to healthcare access and/or
184 housing or proxies of occupation (household income, educational attainment, apartment
185 building density, and social assistance);^{47,48} and unmeasured confounders related to
186 race/ethnicity (visible minority status and recent immigration).^{13,14} These determinants
187 were derived from available measures within the long-form 2016 Canada Census at the

188 level of dissemination areas (DA), which are the smallest geographic unit that Census
189 data are disseminated.⁴⁹ DAs were ranked at the city level (for median per-person
190 income equivalent) or at the province level (for all other social determinants), and then
191 categorized into quintiles. For apartment building density and recent immigration, the
192 high frequency of zeros permitted the creation of only three categories (i.e., comparing
193 the fourth and fifth quintiles with the lowest 60%). Variable definitions are detailed in
194 **eTable1**.

195

196 Statistical analysis

197 To identify determinants of testing, the outcome was defined as receipt of at least one
198 SARS-CoV-2 test during the study period. The comparator group comprised Ontario
199 residents who did not have a record of testing during the study period. Determinants of
200 testing were examined in unadjusted, age/sex-adjusted, and fully-adjusted logistic
201 regression models that included all determinants. The fully-adjusted model also
202 included a fixed-effect covariate for public health region. These are geographic areas in
203 which public health measures were differentially applied⁵⁰ and along which there may
204 be considerable variability in measured and unmeasured social determinants.⁵¹ We
205 opted to include public health regions *a priori* in the model due to these predicted
206 variations in public health response.

207

208 To identify determinants of COVID-19, the outcome variable was a laboratory-confirmed
209 diagnosis. To explore the potential for effects of a variety of sources of bias from testing,
210 we compared the results according to different comparison sub-groups, by

211 characteristics that may have influenced the probability of being tested. We first
212 compared individuals who tested positive to individuals who tested negative (“pseudo-
213 test-negative design”). Second, we restricted the analysis to individuals with
214 symptomatic illness, mirroring the test-negative design commonly used to assess
215 influenza vaccine effectiveness (the “true test-negative design”).⁵² Third, we compared
216 all individuals who tested positive to all individuals who did *not* test positive (i.e., to
217 individuals who tested negative or were not tested; the “case-control design”). Potential
218 mechanisms of selection biases in each analytic design are outlined in **eFigure 1A-C**.
219
220 We then conducted unadjusted, age/sex-adjusted, and fully-adjusted logistic regression
221 models (including all determinants and public health region, as with testing) using each
222 of the three analytic approaches to identify heterogeneity in individual, environmental,
223 and social determinants of COVID-19 diagnosis. We interpreted each set of
224 determinants (individual, environmental, social) as independent analyses based on the
225 directed acyclic graphs (**eFigure 1A-C**). Statistical analyses were conducted using SAS
226 v. 9.4 (Cary, NC).

227

228 *Ethical review*

229 The use of data in this project was authorized under section 45 of Ontario’s Personal
230 Health Information Protection Act, which does not require review by a Research Ethics
231 Board.

232

233 **Results**

234 Of 758,691 individuals tested during the study period, 25,030 (3.3%) received a
235 laboratory-confirmed diagnosis (**Figure 1**). Only 11.8% of those tested had a symptom
236 recorded by the provider, 13.6% were considered asymptomatic, and 74.6% were
237 missing symptom information. **Table 1** describes the characteristics of the study
238 population.

239

240 *Determinants of SARS-CoV-2 testing*

241 In fully-adjusted analyses, odds of testing increased with age (**Table 2**). Males had
242 lower odds of testing than females. Nearly every underlying health condition was
243 associated with increased odds of testing, as were most measures of prior healthcare
244 use. In contrast, higher measures of ambient air pollution were associated with reduced
245 odds of testing. There was little variability in the odds of testing by most area-based
246 social determinants. However, areas with higher visible minority populations had lower
247 odds of testing, whereas areas with higher household income and greater percentages
248 of uncoupled individuals had higher odds of testing. Effect measures across nearly all
249 determinants appeared to be progressively attenuated from unadjusted, to age/sex-
250 adjusted, to fully-adjusted regression models (**eTable 2**).

251

252 *Variability in determinants of COVID-19 diagnosis across three analytic approaches*

253 Choice of analytic design and comparison group restrictions had substantial influences
254 on the magnitude and direction of the association between individual-level determinants
255 and diagnosis (**Table 2**). Determinants associated with odds of testing further from the
256 null appeared to be more variable in terms of odds of diagnosis across analytic designs.

257 For example, the odds of testing for adults aged ≥ 85 years compared to those aged < 5
258 years deviated considerably from the null (adjusted odds ratio [aOR]=5.57; 95%CI,
259 5.45-5.70), and the odds of diagnosis differed between the pseudo-test-negative design
260 (aOR=1.72; 95%CI, 1.48-2.01), the true test-negative design (aOR=5.95; 95%CI, 3.57-
261 9.92), and the case-control design (aOR=7.09; 95%CI, 6.08-8.26). Some health
262 conditions associated with higher odds of testing, such as chronic respiratory conditions,
263 and indicators of prior healthcare use appeared protective against COVID-19 using the
264 pseudo-test-negative design, but reverted to the null or showed increased odds of
265 diagnosis using the case-control design. As with testing, effect measures for COVID-19
266 diagnosis across all determinants appeared to be progressively attenuated from
267 unadjusted, to age/sex-adjusted, to fully-adjusted regression models (**eTables 3-5**).

268

269 *Individual determinants of COVID-19 diagnosis using the case-control design*

270 Using the case-control design, age, certain comorbidities (e.g., hypertension, diabetes,
271 dementia), and increased prior healthcare use were associated with increased odds of
272 COVID-19. In contrast, other comorbidities (e.g., cancer, substance abuse) and receipt
273 of influenza vaccine in the 2019-2020 season were associated with reduced odds of
274 diagnosis (**Table 2**).

275

276 *Environmental determinants of COVID-19 diagnosis using the case-control design*

277 The two highest categories of $PM_{2.5}$ exposure were associated with increased odds of
278 diagnosis, whereas no categories of exposure to NO_2 were associated with increased
279 odds of diagnosis consistently across analytic approaches.

280

281 *Social determinants of COVID-19 diagnosis using the case-control design*

282 Area-level social determinants independently associated with COVID-19 included higher
283 household income, increased receipt of social assistance, lower educational attainment,
284 greater percentages of uncoupled individuals, higher household density, increased
285 apartment building density, and greater percentages of recent immigrants.

286

287 **Figures 2A** and **2B** highlight the changes from unadjusted to fully-adjusted models for
288 the associations between area-level social determinants and testing and diagnosis,
289 respectively. For testing, the associations were attenuated after adjustment for nearly all
290 determinants. The association for household income reversed direction following
291 adjustment. For diagnosis, the associations were attenuated after adjustment for all
292 social determinants except for household density. Similar to testing, the association with
293 COVID-19 for household income reversed direction following adjustment.

294

295 **Discussion**

296 In this large-scale, population-based study, we identified social determinants as key
297 potential determinants for a diagnosis of COVID-19. We identified variability in
298 associations, likely due to selection biases, by analytic design across individual
299 determinants of COVID-19 diagnosis.

300

301 We identified increased odds of diagnosis associated with household density,
302 educational attainment, uncoupled status, and recent immigration, consistent with

303 findings from other settings.^{51,53,54} In particular, the results concerning social
304 determinants and COVID-19 risk presented here suggest these social determinants are
305 not likely artifacts of selection bias from study design, given the consistency of findings
306 across different analytic approaches. Lower educational attainment or uncoupled status
307 may be associated with higher exposure risk through lower-paying jobs in the service
308 industry⁵⁵ and/or other high-exposure occupations, either because those jobs cannot be
309 done feasibly with proper protections, or because protective policies fail to be issued,
310 leaving workers at high risk.^{56,57} Higher percentages of recent immigrants in an area
311 were associated with COVID-19 diagnosis, even after adjustment, although the
312 percentage of visible minorities was not. Both variables might represent residual
313 measures of mediators of systemic racism, potentiating relative risks of SARS-CoV-2
314 exposure and COVID-19 severity,⁵⁸⁻⁶⁰ including COVID-19-related
315 hospitalization/death.^{14,21,30,54} We found that an association between visible minority and
316 COVID-19 diagnosis in Ontario was attenuated after adjustment for individual,
317 environmental, and other social determinants. These findings likely reflect what is
318 already known about race and ethnicity as social constructs and social determinants of
319 health.⁶¹ This is further supported by the attenuation of effect estimates from the
320 unadjusted, to age/sex-adjusted, to fully-adjusted models. Finally, the fact that there
321 was little variation in the odds of testing rates across levels of most of the social
322 determinants suggests that testing resources may not be prioritizing those who are most
323 at risk.⁶² However, even with this finding, our results indicate that social determinants of
324 health play important roles in determining COVID-19 risk. Taken together, our findings
325 suggest a need to increase and/or redirect resources that specifically address social

326 determinants such as household density^{48,63} (e.g., voluntary temporary isolation
327 hotels⁶⁴), proxies for occupational risk^{56,60} (e.g., paid sick leave⁶⁵), and other mediators
328 of systemic racism^{62,66,67} (e.g. community-led outreach testing⁶⁸).

329
330 We also identified the size and direction of influence that selection biases may have,
331 adding to the ongoing conversation on the challenges of interpreting determinants for
332 COVID-19 due to collider bias.²² Although we did not directly explore each potential
333 collider mechanism, the pattern that emerged was that underlying health conditions
334 associated with COVID-19 severity² may have been prone to collider bias, as evidenced
335 by higher testing and a seemingly protective effect when using the test-negative designs
336 that reversed when using the case-control design. It is, however, also possible that a
337 high number of covariates in fully-adjusted models caused instability in effect measure
338 estimates for these covariates. Age also demonstrated a similar potential susceptibility
339 to collider bias, possibly mediated by COVID-19 severity and symptoms (i.e., older age
340 groups are more likely to develop severe/symptomatic infection if infected²). Over the
341 study period, the testing criteria in Ontario shifted from returning symptomatic travellers
342 to severely symptomatic individuals and those with occupational exposure to additional
343 testing of asymptomatic individuals.^{33-36,38} In our study, the restriction of the test-
344 negative design to symptomatic individuals did not yield substantially different results
345 than the test-negative design including symptomatic and asymptomatic individuals, but
346 that may have been partly due to the extensive (74.6%) missingness of symptom
347 reporting in the testing data. We opted not to use multiple imputation methods to
348 determine symptom information because, at the time the analysis was conducted,

349 reported symptoms of COVID-19 were highly variable and the extent to which
350 individuals may have asymptomatic or pre-symptomatic illness was unclear, limiting our
351 confidence in the generalizability of existing information to individuals whose information
352 was missing. Thus, while there is an intuitive desire to compare test positivity rates
353 among those tested—a common metric of comparison across surveillance reports and
354 dashboards^{69,70}—the risks of erroneously identifying a “risk/protective factor”,
355 particularly individual determinants such as underlying health conditions, sex, and age,
356 are high and deserve careful interpretation by examining, as best possible, the reasons
357 for testing.²² In the context of low overall levels of testing, the case-control design may
358 have mitigated some potential sources of selection bias, with the assumption that those
359 not tested are similar to those who tested negative.^{21,22} Additionally, we found that some
360 underlying health conditions and prior healthcare use remained associated with
361 diagnoses, reflecting either unmeasured confounders or possible biological
362 susceptibility to infection if exposed;^{15,16,71-73} and suggesting that strategies tailored to
363 reduce exposures among individuals characterized by these individual determinants
364 could also be important in risk-tailored prevention.

365
366 Finally, these analyses identified PM_{2.5} as being related to the odds of COVID-19. It is
367 likely that some of this effect is due to underlying social determinants of health and
368 access to tests. Air pollution is often more intense, and results in worse health
369 outcomes, in areas with higher social deprivation.^{74,75} However, existing studies have
370 also implicated environmental pollution as having a biological relationship to the risk and
371 severity of COVID-19 and other respiratory infections.^{15,16,19} Taken together with other

372 findings regarding social determinants of health, these results indicate the importance of
373 considering air pollution and particulate matter in both individual- and area-directed
374 COVID-19 interventions.

375

376 **Limitations**

377 Our diagnoses were restricted to laboratory-confirmed cases and to the 88% of
378 diagnoses available via OLIS, and thus could miss probable cases as well as the
379 remaining laboratory-confirmed cases that may have different determinants of infection.

380

381 Results are also conditioned on the assumption that determinants remained constant
382 across the study period, whereas surveillance data suggest shifts in how infections
383 propagate between social networks.⁷⁶ Future analyses include examining changes in
384 the direction and magnitude of determinants over the course of the outbreak. Although
385 we generated directed acyclic graphs for the general categories of determinants to help
386 conceptualize and mitigate selection bias while also identifying plausible determinants, it
387 is possible that we over-adjusted when interpreting individual variables within each
388 category.⁷⁷ Our models also adjusted for public health region, within which many social
389 determinants cluster⁵¹, and thus we cannot infer from the results presented how social
390 determinants of COVID-19 risk may vary between and within these geographic regions.
391 Social determinants were measured at the area level and were not available at the
392 individual level; however, by describing individuals' neighbourhoods, analyses reflect
393 the role of structural and environmental determinants for individuals living amongst them.
394 Some important determinants identified in the prior literature, such as obesity,^{8,78} were

395 not available for our study.⁷⁹ Others, such as occupation, were not included due to
396 uncertainty related to quantifying and appropriately grouping the occupational
397 classifications available in the Census data at the area level.

398

399 **Conclusion**

400 Individual-level risks for COVID-19 defined by demographic and health-related
401 determinants representing general targets of current response strategies appear to be
402 subject to selection bias, including collider bias. Moving forward and advancing the
403 response necessitates characterizing and addressing the social determinants
404 potentiating heterogeneity in COVID-19 acquisition and transmission risks with risk-
405 tailored, community-based interventions to reduce COVID-19 burden.

406

407

408 **Funding Statement**

409 This study was funded by the St. Michael's Hospital Research Innovation Council
410 COVID-19 Research Grant, and research operating grant (VR5 -172683) from the
411 Canadian Institutes of Health Research. SM is supported by a Tier 2 Canada Research
412 Chair in Mathematical Modeling and Program Science. JCK is supported by a Clinician-
413 Scientist Award from the University of Toronto Department of Family and Community
414 Medicine. This study was supported by ICES, which is funded by an annual grant from
415 the Ontario Ministry of Health and Long-Term Care (MOHLTC). The study sponsors did
416 not participate in the design and conduct of the study; collection, management, analysis

417 and interpretation of the data; preparation, review or approval of the manuscript; or the
418 decision to submit the manuscript for publication.

419

420 **Disclaimers:** The opinions, results, and conclusions reported in this paper are those of
421 the authors and are independent from the funding sources. Parts of this material are
422 based on data and/or information compiled and provided by the Canadian Institute for
423 Health Information (CIHI) and by Cancer Care Ontario (CCO). However, the analyses,
424 conclusions, opinions, and statement expressed herein are those of the authors, and
425 not necessarily those of CIHI or CCO. No endorsement by ICES, MOHLTC, CIHI, or
426 CCO is intended or should be inferred.

427

428 **Acknowledgements:** We thank IMS Brogan Inc. for use of their Drug Information
429 Database. Finally, we are grateful to the 14.7 million Ontario residents without whom
430 this research would be impossible.

431

432 **Author contributions:**

433 JK, SM, and SB designed the study. ACa conducted all data analyses (dataset and
434 variable creation and statistical modeling). JK, SM, SB, RK, ACa designed the analyses
435 plans and conducted variable selection, with input from HC and ACK on variable
436 selection and definitions. MAH, MD, LCR, TW contributed to analytic plans related to
437 collider bias. BC contributed to data analyses and data preparation for the symptomatic
438 dataset. MS prepared the figures. MS, JK, SB, and SM wrote the manuscript. All
439 authors interpreted the data and critically reviewed and edited the manuscript.

441 **References**

- 442
- 443 1. Mishra S, Kwong JC, Chan AK, Baral SD. Understanding heterogeneity to inform
444 public health response to COVID-19 in Canada. *Can Med Assoc J.*
445 2020;192(25):E684-E685.
 - 446 2. *Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-*
447 *19)*. Geneva, Switzerland: World Health Organization; 16-24 February, 2020
448 2020.
 - 449 3. Rosenberg ES, Dufort EM, Blog DS, et al. COVID-19 Testing, Epidemic Features,
450 Hospital Outcomes, and Household Prevalence, New York State-March 2020.
451 *Clinical infectious diseases : an official publication of the Infectious Diseases*
452 *Society of America.* 2020.
 - 453 4. Jing Q-L, Liu M-J, Yuan J, et al. Household secondary attack rate of COVID-19
454 and associated determinants. *medRxiv pre-print.* 2020.
 - 455 5. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children —
456 United States, February 12-April 2, 2020. *Morbidity and Mortality Weekly Report.*
457 2020;69(14):422-426.
 - 458 6. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses
459 that underlie COVID-19 disease outcomes. *Nature.* 2020.
 - 460 7. Stall NM, Wu W, Lapointe-Shaw L, et al. Sex- and age-specific differences in
461 COVID-19 testing, cases and outcomes: a population-wide study in Ontario,
462 Canada. *J Am Geriatr Soc.* 2020.
 - 463 8. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and
464 male sex are independently associated with worse in-hospital outcomes, and
465 higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx,
466 New York. *Metabolism.* 2020;108:154262.
 - 467 9. Abrams E, Szeffler S. COVID-19 and the impact of social determinants of health.
468 *The New England journal of medicine.* 2020;382(21):2061-2063.
 - 469 10. Bhalra N, Curry G, Martineau AR, Agyemang C, Bhopal R. Sharpening the global
470 focus on ethnicity and race in the time of COVID-19. *The Lancet.*
 - 471 11. Chung H, Fung K, Ferreira-Legere LE, et al. *COVID-19 Laboratory Testing in*
472 *Ontario: Patterns of Testing and Characteristics of Individuals Tested, as of April*
473 *30, 2020.* ICES Ontario;2020.
 - 474 12. Wang L, Mishra S. *The distribution of cumulative COVID-19 cases in Ontario by*
475 *acquisition type over time.* 2020.
 - 476 13. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality
477 among Black Patients and White Patients with Covid-19. *The New England*
478 *journal of medicine.* 2020;382(26):2534-2543.
 - 479 14. Yehia BR, Winegar A, Fogel R, et al. Association of Race With Mortality Among
480 Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US
481 Hospitals. *JAMA Netw Open.* 2020;3(8):e2018039.
 - 482 15. Feng C, Li J, Sun W, Zhang Y, Wang Q. Impact of ambient fine particulate matter
483 (PM_{2.5}) exposure on the risk of influenza-like-illness: a time-series analysis in
484 Beijing, China. *Environ Health.* 2016;15:17.

- 485 16. Zoran MA, Savastru RS, Savastru DM, Tautan MN. Assessing the relationship
486 between surface levels of PM2.5 and PM10 particulate matter impact on COVID-
487 19 in Milan, Italy. *Sci Total Environ.* 2020;738:139825.
- 488 17. Wu X, Nethery RC, Sabath BM, Braun D, Dominici F. Exposure to air pollution
489 and COVID-19 mortality in the United States: A nationwide cross-sectional study.
490 *medRxiv.* 2020.
- 491 18. Liang D, Shi L, Zhao J, et al. Urban Air Pollution May Enhance COVID-19 Case-
492 Fatality and Mortality Rates in the United States. *medRxiv.* 2020.
- 493 19. Wu X, Nethery R, Sabath M, Braun D, Dominici F. Exposure to air pollution and
494 COVID-19 mortality in the United States: a nationwide cross-sectional study.
495 *medRxiv.* 2020.
- 496 20. Environmental racism: time to tackle social injustice. *The Lancet Planetary*
497 *Health.* 2018;2(11).
- 498 21. Niedzwiedz CL, O'Donnell CA, Jani BD, et al. Ethnic and socioeconomic
499 differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank.
500 *BMC Med.* 2020;18(1):160.
- 501 22. Griffith G, Morris T, Tudball M, et al. Collider bias undermines our understanding
502 of COVID-19 disease risk and severity. *medRxiv.* 2020.
- 503 23. Hernán M, Robins J. *Causal Inference.* 2014.
- 504 24. Elwert F, Winship C. Endogenous Selection Bias: The Problem of Conditioning
505 on a Collider Variable. *Annu Rev Sociol.* 2014;40:31-53.
- 506 25. Health care in Ontario: OHIP. <https://www.ontario.ca/page/health-care-ontario>.
507 Published 2020. Accessed October 29, 2020.
- 508 26. *Schedule of benefits for laboratory services.* Ontario: Ministry of Health, Ontario
509 Health Insurance Plan, Laboratories and Genetics Branch; July 1 2020.
- 510 27. IC/ES: Data, Discovery, Better Health. <https://www.ices.on.ca>. Published 2020.
511 Accessed October 29, 2020.
- 512 28. Data products, 2016 Census. Statistics Canada/Statistique Canada.
513 <https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/index-eng.cfm>.
514 Published 2020. Accessed October 29, 2020.
- 515 29. Pennington E. Asthma increases risk of severity of COVID-19. *Cleve Clin J Med.*
516 2020.
- 517 30. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated
518 with COVID-19 death in 17 million patients. *Nature.* 2020.
- 519 31. Fang L, Karakiulakis G, Roth M. Are patients with hyperetension and diabetes
520 mellitus at increased risk for COVID-19 infection? *Lancet Respiratory Medicine.*
521 2020;8:e21.
- 522 32. Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with
523 COVID-19 versus patients with influenza. *medRxiv.* 2020.
- 524 33. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: May*
525 *14, 2020.* May 14 2020.
- 526 34. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: May 2,*
527 *2020.* May 2 2020.
- 528 35. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: April*
529 *15, 2020.* April 15 2020.

- 530 36. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: May*
531 *28, 2020*. May 28 2020.
- 532 37. Ontario Ministry of Health. *COVID-19 Quick Reference Public Health Guidance*
533 *on Testing and Clearance: March 27, 2020*. 2020.
- 534 38. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: April*
535 *8, 2020*. April 8, 2020 2020.
- 536 39. Tolea MI, Morris JC, Galvin JE. Trajectory of Mobility Decline by Type of
537 Dementia. *Alzheimer Dis Assoc Disord*. 2016;30(1):60-66.
- 538 40. Chiao C-Y, Wu H-S, Hsiao C-Y. Caregiver burden for informal caregivers of
539 patients with dementia: A systematic review. *Int Nurs Rev*. 2015;62(3):340-350.
- 540 41. Johns Hopkins ACG(c) System. Johns Hopkins. <https://www.hopkinsacg.org>.
541 Published 2020. Accessed November 1, 2020.
- 542 42. Austin PC, van Walraven C, Wodchis WP, Newman A, Anderson GM. Using the
543 Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a
544 general adult population cohort in Ontario, Canada. *Med Care*. 2011;49(10):932-
545 939.
- 546 43. van Donkelaar A, Martin RV, Brauer M, Boys BL. Use of Satellite Observations
547 for Long-Term Exposure Assessment of Global Concentrations of Fine
548 Particulate Matter. *Environ Health Perspect*. 2015;123:135-143.
- 549 44. Hystad P, Setton E, Cervantes A, et al. Creating national air pollution models for
550 population exposure assessment in Canada. *Environ Health Perspect*.
551 2011;119(8):1123-1129.
- 552 45. Walker P, Whittaker C, Watson O, et al. The impact of COVID-19 and strategies
553 for mitigation and suppression in low- and middle-income countries. *Science*.
554 2020;369(6502):413-422.
- 555 46. Park SY, Kim YM, Yi S, et al. Coronavirus Disease Outbreak in Call Center,
556 South Korea. *Emerg Infect Dis*. 2020;26(8):1666-1670.
- 557 47. Karaye IM, Horney JA. The Impact of Social Vulnerability on COVID-19 in the
558 U.S.: An Analysis of Spatially Varying Relationships. *American journal of*
559 *preventive medicine*. 2020;59(3):317-325.
- 560 48. Rodriguez-Diaz CE, Guilamo-Ramos V, Mena L, et al. Risk for COVID-19
561 infection and death among Latinos in the United States: examining heterogeneity
562 in transmission dynamics. *Ann Epidemiol*. 2020.
- 563 49. Statistics Canada/Statistique Canada. Dictionary, Census of Population, 2016.
564 <https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/geo021-eng.cfm>.
565 Published 2020. Accessed October 13, 2020.
- 566 50. Public Health Units. <https://www.ontario.ca/page/public-health-units>. Published
567 2017. Updated March 22, 2019. Accessed October 29, 2020.
- 568 51. *Enhanced epidemiological summary: COVID-19 in Ontario—a focus on diversity*.
569 Public Health Ontario;2020.
- 570 52. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-
571 Negative Study Design for Assessment of Influenza Vaccine Effectiveness.
572 *American journal of epidemiology*. 2016;184(5):345-353.
- 573 53. Lin SL. Intersectionality and inequalities in medical risk for severe COVID-19 in
574 the Canadian Longitudinal Study on Aging. *Gerontologist*. 2020.

- 575 54. Drefahl S, Wallace M, Mussino E, et al. A population-based cohort study of
576 socio-demographic risk factors for COVID-19 deaths in Sweden. *Nat Commun.*
577 2020;11(1):5097.
- 578 55. *Workplace Safety & Prevention Services Guidance on Health and Safety for the*
579 *Personal Care Service Sector during COVID-19.* Ontario: Workplace Safety &
580 Prevention Services;2020.
- 581 56. Dyal J, Grant M, Broadwater K, et al. COVID-19 among workers in meat and
582 poultry processing facilities—19 states, April 2020. *Morbidity and Mortality*
583 *Weekly Report.* 2020;69(18):557-561.
- 584 57. Contrera J. The N95 shortage America can't seem to fix. *Washington Post.*
585 September 21, 2020, 2020.
- 586 58. Vahidy FS, Nicolas JC, Meeks JR, et al. Racial and ethnic disparities in SARS-
587 CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US
588 metropolitan population. *BMJ Open.* 2020;10(8):e039849.
- 589 59. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among
590 patients in the Oxford Royal College of General Practitioners Research and
591 Surveillance Centre primary care network: a cross-sectional study. *The Lancet*
592 *Infectious Diseases.* 2020;20(9):1034-1042.
- 593 60. Liem A, Wang C, Wariyanti Y, Latkin CA, Hall BJ. The neglected health of
594 international migrant workers in the COVID-19 epidemic. *The Lancet Psychiatry.*
595 2020;7(4).
- 596 61. Ordóñez CE. Not race, racism: Concerns of COVID-19 affecting African
597 Americans. *Anthropological Responses to Health Emergencies.* 2020.
- 598 62. Dodds C, Fakoya I. Covid-19: ensuring equality of access to testing for ethnic
599 minorities. *BMJ.* 2020;369:m2122.
- 600 63. Brandén M, Aradhya S, Kolk M, et al. Residential context and COVID-19
601 mortality among adults aged 70 years and older in Stockholm: a population-
602 based, observational study using individual-level data. *The Lancet Healthy*
603 *Longevity.* 2020.
- 604 64. Jordan-Martin NC, Madad S, Alves L, et al. Isolation Hotels: A Community-Based
605 Intervention to Mitigate the Spread of the COVID-19 Pandemic. *Health Secur.*
606 2020.
- 607 65. Vazquez J, Islam T, Beller J, et al. Expanding paid sick leave as a public health
608 tool in the COVID-19 pandemic. *J Occup Environ Med.* 2020;Letter to the Editor.
- 609 66. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic
610 Disparities. *JAMA.* 2020.
- 611 67. Yang TC, Emily Choi SW, Sun F. COVID-19 cases in US counties: roles of
612 racial/ethnic density and residential segregation. *Ethn Health.* 2020:1-11.
- 613 68. Wallis G, Siracusa F, Blank M, et al. Experience of a novel community testing
614 programme for COVID-19 in London: Lessons learnt. *Clin Med (Lond).*
615 2020;20(5):e165-e169.
- 616 69. ICES COVID-19 Dashboard. ICES. <https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard>. Published 2020. Accessed October 29, 2020.
- 617 70. Ontario COVID-19 Data Tool. Public Health Ontario.
618 <https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/covid-19>
619

- 620 [19-data-surveillance/covid-19-data-tool](#). Published 2020. Accessed October 29,
621 2020.
- 622 71. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular
623 disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol*.
624 2020;17(9):543-558.
- 625 72. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes:
626 Knowledge in progress. *Diabetes Res Clin Pract*. 2020;162:108142.
- 627 73. Elliot AJ, Harcourt SE, Hughes HE, et al. The COVID-19 pandemic: a new
628 challenge for syndromic surveillance. *Epidemiol Infect*. 2020;148:e122.
- 629 74. Morelli X, Rieux C, Cyrus J, Forsberg B, Slama R. Air pollution, health and social
630 deprivation: A fine-scale risk assessment. *Environ Res*. 2016;147:59-70.
- 631 75. Næss Ø, Piro FN, Nafstad P, Smith GD, Leyland AH. Air Pollution, Social
632 Deprivation, and Mortality. *Epidemiology*. 2007;18(6):686-694.
- 633 76. Wang L, Ma H, Yiu KCY, et al. Heterogeneity in risk, testing and outcome of
634 COVID-19 across outbreak settings in the Greater Toronto Area, Canada: an
635 observational study. *medRxiv*. 2020.
- 636 77. Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting
637 confounder and modifier coefficients. *American journal of epidemiology*.
638 2013;177(4):292-298.
- 639 78. Kwok S, Adam S, Ho JH, et al. Obesity: A critical risk factor in the COVID-19
640 pandemic. *Clin Obes*. 2020:e12403.
- 641 79. ICES Data Dictionary. ICES.
642 <https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx>.
643 Published 2020. Accessed November 1, 2020.
- 644 80. In: NAAQS Table, ed. Washington, DC: United States Environmental Protection
645 Agency.
646
647
648
649
650

Table 1. Characteristics of study population tested and not tested for SARS-CoV-2 in Ontario (March 1, 2020 to June 20, 2020).

	Tested individuals		Symptomatic tested individuals only		All individuals	
	Tested negative (N = 733,661)	Tested positive (N = 25,030)	Tested negative and symptomatic (N = 85,355)	Tested positive and symptomatic (N = 4,053)	Untested control group (N = 13,936,888)	All tested (N = 758,691)
Demographic characteristics						
Age: mean (SD)	49.52 ± 20.99	47.45 ± 19.77	47.91 ± 20.80	50.83 ± 20.39	40.31 ± 22.91	49.45 ± 20.95
Age groups (years)						
0-4	10,870 (1.5%)	223 (0.9%)	1,627 (1.9%)	17 (0.4%)	727,305 (5.2%)	11,093 (1.5%)
5-19	33,642 (4.6%)	1,149 (4.6%)	4,017 (4.7%)	125 (3.1%)	2,395,518 (17.2%)	34,791 (4.6%)
20-34	157,086 (21.4%)	6,015 (24.0%)	19,431 (22.8%)	864 (21.3%)	2,810,230 (20.2%)	163,101 (21.5%)
35-49	160,506 (21.9%)	6,084 (24.3%)	20,495 (24.0%)	934 (23.0%)	2,772,204 (19.9%)	166,590 (22.0%)
50-64	192,178 (26.2%)	7,009 (28.0%)	21,329 (25.0%)	1,159 (28.6%)	2,865,926 (20.6%)	199,187 (26.3%)
65-74	84,077 (11.5%)	2,072 (8.3%)	8,765 (10.3%)	386 (9.5%)	1,394,043 (10.0%)	86,149 (11.4%)
75-84	52,655 (7.2%)	1,284 (5.1%)	5,181 (6.1%)	251 (6.2%)	713,639 (5.1%)	53,939 (7.1%)
≥85	42,647 (5.8%)	1,194 (4.8%)	4,510 (5.3%)	317 (7.8%)	258,023 (1.9%)	43,841 (5.8%)
Male sex: N (%)	289,769 (39.5%)	11,627 (46.5%)	33,078 (38.8%)	1,898 (46.8%)	6,930,233 (49.7%)	301,396 (39.7%)
Living in rural/small town: N (%) ^a	82,034 (11.2%)	887 (3.5%)	14,140 (16.6%)	304 (7.5%)	1,390,426 (10.0%)	82,921 (10.9%)
Public Health region						
Central East	59,951 (8.2%)	707 (2.8%)	7,898 (9.3%)	193 (4.8%)	874,010 (6.3%)	60,658 (8.0%)
Central West	136,116 (18.6%)	3,375 (13.5%)	17,469 (20.5%)	951 (23.5%)	2,683,999 (19.3%)	139,491 (18.4%)
Durham	30,618 (4.2%)	1,244 (5.0%)	1,341 (1.6%)	125 (3.1%)	671,605 (4.8%)	31,862 (4.2%)
Eastern	53,097 (7.2%)	466 (1.9%)	9,752 (11.4%)	152 (3.8%)	829,504 (6.0%)	53,563 (7.1%)
North	56,977 (7.8%)	308 (1.2%)	14,442 (16.9%)	177 (4.4%)	761,495 (5.5%)	57,285 (7.6%)
Ottawa	52,754 (7.2%)	1,360 (5.4%)	3,761 (4.4%)	190 (4.7%)	980,501 (7.0%)	54,114 (7.1%)
Peel	63,093 (8.6%)	4,464 (17.8%)	5,780 (6.8%)	376 (9.3%)	1,465,044 (10.5%)	67,557 (8.9%)
South West	87,412 (11.9%)	2,040 (8.2%)	9,101 (10.7%)	673 (16.6%)	1,609,925 (11.6%)	89,452 (11.8%)
Toronto	140,217 (19.1%)	8,728 (34.9%)	10,360 (12.1%)	797 (19.7%)	2,761,786 (19.8%)	148,945 (19.6%)
York	48,565 (6.6%)	2,119 (8.5%)	5,068 (5.9%)	376 (9.3%)	1,157,124 (8.3%)	50,684 (6.7%)
Underlying chronic health conditions						
Asthma	136,556 (18.6%)	3,887 (15.5%)	17,831 (20.9%)	671 (16.6%)	2,085,118 (15.0%)	140,443 (18.5%)
COPD	34,261 (4.7%)	715 (2.9%)	4,616 (5.4%)	168 (4.1%)	249,636 (1.8%)	34,976 (4.6%)

Hypertension	226,111 (30.8%)	7,488 (29.9%)	24,364 (28.5%)	1,313 (32.4%)	2,836,790 (20.4%)	233,599 (30.8%)
Diabetes	108,758 (14.8%)	4,268 (17.1%)	11,763 (13.8%)	684 (16.9%)	1,363,667 (9.8%)	113,026 (14.9%)
Congestive heart failure	35,947 (4.9%)	983 (3.9%)	3,864 (4.5%)	194 (4.8%)	225,153 (1.6%)	36,930 (4.9%)
Dementia or frailty	31,804 (4.3%)	1,106 (4.4%)	3,399 (4.0%)	296 (7.3%)	124,295 (0.9%)	32,910 (4.3%)
Cancer ^p	24,333 (3.3%)	484 (1.9%)	2,333 (2.7%)	89 (2.2%)	213,036 (1.5%)	24,817 (3.3%)
Chronic kidney disease ^b	37,630 (5.1%)	1,122 (4.5%)	3,581 (4.2%)	199 (4.9%)	254,541 (1.8%)	38,752 (5.1%)
Immunocompromised ^c	13,325 (1.8%)	319 (1.3%)	1,496 (1.8%)	57 (1.4%)	107,824 (0.8%)	13,644 (1.8%)
Advanced liver disease	9,020 (1.2%)	212 (0.8%)	1,045 (1.2%)	35 (0.9%)	78,747 (0.6%)	9,232 (1.2%)
Ischemic heart disease	33,855 (4.6%)	880 (3.5%)	3,773 (4.4%)	168 (4.1%)	324,682 (2.3%)	34,735 (4.6%)
Ischemic stroke or TIA ^d	13,777 (1.9%)	411 (1.6%)	1,531 (1.8%)	77 (1.9%)	99,503 (0.7%)	14,188 (1.9%)
Schizophrenia ^e	7,526 (1.0%)	220 (0.9%)	732 (0.9%)	42 (1.0%)	64,494 (0.5%)	7,746 (1.0%)
Substance abuse ^e	22,238 (3.0%)	478 (1.9%)	3,001 (3.5%)	59 (1.5%)	216,156 (1.6%)	22,716 (3.0%)
Healthcare use						
Adjusted Diagnostic Group quintile						
1 (0 ADGs)	31,959 (4.4%)	1,571 (6.3%)	3,006 (3.5%)	247 (6.1%)	1,616,852 (11.6%)	33,530 (4.4%)
2 (1-2 ADGs)	101,895 (13.9%)	3,601 (14.4%)	11,419 (13.4%)	595 (14.7%)	3,150,969 (22.6%)	105,496 (13.9%)
3 (3-4 ADGs)	149,173 (20.3%)	5,101 (20.4%)	17,220 (20.2%)	782 (19.3%)	3,385,602 (24.3%)	154,274 (20.3%)
4 (5-6 ADGs)	150,394 (20.5%)	5,115 (20.4%)	17,736 (20.8%)	822 (20.3%)	2,626,403 (18.8%)	155,509 (20.5%)
5 (7-27 ADGs)	300,240 (40.9%)	9,642 (38.5%)	35,974 (42.1%)	1,607 (39.6%)	3,157,062 (22.7%)	309,882 (40.8%)
Hospital admissions, past 3 years: Mean (SD)	0.44 ± 1.34	0.33 ± 1.21	0.45 ± 1.29	0.36 ± 1.09	0.19 ± 0.60	0.44 ± 1.34
Outpatient physician visits, past year: Mean (SD)	7.35 ± 8.68	7.06 ± 8.33	7.15 ± 8.40	7.07 ± 8.64	4.67 ± 6.05	7.34 ± 8.67
Influenza vaccination (2019-2020 season)	213,722 (29.1%)	5,547 (22.2%)	23,429 (27.4%)	1,019 (25.1%)	2,978,472 (21.4%)	219,269 (28.9%)
Environmental determinants^f						
PM_{2.5} category (µg/m³ yearly)						
2 to <6	161,300 (22.0%)	1,831 (7.3%)	27,764 (32.5%)	556 (13.7%)	2,481,201 (17.8%)	163,131 (21.5%)
6 to <7	91,134 (12.4%)	1,766 (7.1%)	10,930 (12.8%)	318 (7.8%)	1,555,790 (11.2%)	92,900 (12.2%)
7 to <8	207,966 (28.3%)	8,476 (33.9%)	21,183 (24.8%)	1,281 (31.6%)	4,450,218 (31.9%)	216,442 (28.5%)
8 to <9	211,861 (28.9%)	11,127 (44.5%)	19,639 (23.0%)	1,363 (33.6%)	4,258,069 (30.6%)	222,988 (29.4%)
≥9	59,674 (8.1%)	1,747 (7.0%)	5,749 (6.7%)	517 (12.8%)	1,073,665 (7.7%)	61,421 (8.1%)
NO₂ category (parts per billion yearly)						
0 to 6	328,613 (44.8%)	5,237 (20.9%)	48,579 (56.9%)	1,500 (37.0%)	5,505,976 (39.5%)	333,850 (44.0%)

6 to 8	170,693 (23.3%)	5,599 (22.4%)	17,477 (20.5%)	1,079 (26.6%)	3,409,506 (24.5%)	176,292 (23.2%)
≥8	232,629 (31.7%)	14,111 (56.4%)	19,209 (22.5%)	1,456 (35.9%)	4,903,460 (35.2%)	246,740 (32.5%)
Social determinants of health^g (area-level)						
Household income quintile^h						
1 (lowest income)	156,320 (21.3%)	7,000 (28.0%)	17,159 (20.1%)	857 (21.1%)	2,679,780 (19.2%)	163,320 (21.5%)
2	148,687 (20.3%)	5,288 (21.1%)	17,057 (20.0%)	757 (18.7%)	2,698,807 (19.4%)	153,975 (20.3%)
3	145,317 (19.8%)	5,084 (20.3%)	16,771 (19.6%)	756 (18.7%)	2,791,340 (20.0%)	150,401 (19.8%)
4	140,352 (19.1%)	4,019 (16.1%)	17,162 (20.1%)	730 (18.0%)	2,809,529 (20.2%)	144,371 (19.0%)
5 (highest income)	138,103 (18.8%)	3,419 (13.7%)	16,822 (19.7%)	910 (22.5%)	2,815,238 (20.2%)	141,522 (18.7%)
Social assistance quintile (percentage of individuals in the area receiving governmental transfer payments)						
1 (38.0 - 63.5%)	141,146 (19.2%)	3,829 (15.3%)	15,784 (18.5%)	764 (18.9%)	3,016,045 (21.6%)	144,975 (19.1%)
2 (63.5 - 67.2%)	145,846 (19.9%)	4,719 (18.9%)	16,188 (19.0%)	794 (19.6%)	3,004,958 (21.6%)	150,565 (19.8%)
3 (67.2 - 70.8%)	137,208 (18.7%)	4,987 (19.9%)	16,155 (18.9%)	851 (21.0%)	2,658,737 (19.1%)	142,195 (18.7%)
4 (70.8 - 75.3%)	136,423 (18.6%)	4,952 (19.8%)	16,691 (19.6%)	736 (18.2%)	2,433,304 (17.5%)	141,375 (18.6%)
5 (75.3 - 98.1%)	160,519 (21.9%)	6,092 (24.3%)	19,144 (22.4%)	822 (20.3%)	2,571,707 (18.5%)	166,611 (22.0%)
Limited educational attainment quintile (percentage of adults aged 25-64 in the area not having received any diploma)						
1 (0.0 - 4.1%)	144,457 (19.7%)	3,903 (15.6%)	15,245 (17.9%)	709 (17.5%)	2,926,432 (21.0%)	148,360 (19.6%)
2 (4.1 - 7.5%)	154,215 (21.0%)	4,477 (17.9%)	17,690 (20.7%)	869 (21.4%)	2,978,444 (21.4%)	158,692 (20.9%)
3 (7.5 - 11.4%)	151,457 (20.6%)	5,052 (20.2%)	17,765 (20.8%)	759 (18.7%)	2,888,525 (20.7%)	156,509 (20.6%)
4 (11.4 - 17.1%)	148,159 (20.2%)	5,314 (21.2%)	18,014 (21.1%)	847 (20.9%)	2,659,544 (19.1%)	153,473 (20.2%)
5 (17.1 - 94.3%)	129,580 (17.7%)	6,010 (24.0%)	16,160 (18.9%)	824 (20.3%)	2,333,134 (16.7%)	135,590 (17.9%)
Uncoupled quintile (percent of individuals)						
1 (11.2 - 33.7%)	150,044 (20.5%)	3,539 (14.1%)	20,243 (23.7%)	824 (20.3%)	3,130,907 (22.5%)	153,583 (20.2%)
2 (33.7 - 38.4%)	128,561 (17.5%)	3,915 (15.6%)	15,262 (17.9%)	779 (19.2%)	2,698,847 (19.4%)	132,476 (17.5%)
3 (38.5 - 43.6%)	127,689 (17.4%)	4,632 (18.5%)	14,539 (17.0%)	693 (17.1%)	2,579,005 (18.5%)	132,321 (17.4%)
4 (43.6 - 51.0%)	145,560 (19.8%)	5,591 (22.3%)	15,894 (18.6%)	713 (17.6%)	2,633,710 (18.9%)	151,151 (19.9%)
5 (51.0 - 94.6%)	174,985 (23.9%)	7,037 (28.1%)	18,781 (22.0%)	976 (24.1%)	2,732,838 (19.6%)	182,022 (24.0%)

Household density quintile (range of persons per dwelling)						
1 (0 – 2.1)	162,623 (22.2%)	3,639 (14.5%)	20,066 (23.5%)	672 (16.6%)	2,474,391 (17.8%)	166,262 (21.9%)
2 (2.2 - 2.4)	140,653 (19.2%)	3,104 (12.4%)	19,406 (22.7%)	662 (16.3%)	2,368,013 (17.0%)	143,757 (18.9%)
3 (2.5 - 2.6)	104,896 (14.3%)	2,721 (10.9%)	13,059 (15.3%)	531 (13.1%)	1,866,317 (13.4%)	107,617 (14.2%)
4 (2.7 - 3)	166,089 (22.6%)	6,321 (25.3%)	17,843 (20.9%)	1,096 (27.0%)	3,291,097 (23.6%)	172,410 (22.7%)
5 (3.1 - 5.7)	152,578 (20.8%)	8,929 (35.7%)	14,345 (16.8%)	1,024 (25.3%)	3,775,489 (27.1%)	161,507 (21.3%)
Apartment building density category (percent of buildings that are apartment buildings in the area^{ij})						
1 (0 – 7.3%)	391,477 (53.4%)	12,377 (49.4%)	46,693 (54.7%)	2,243 (55.3%)	7,994,323 (57.4%)	403,854 (53.2%)
2 (7.4 - 37.7%)	145,108 (19.8%)	3,874 (15.5%)	19,348 (22.7%)	739 (18.2%)	2,478,855 (17.8%)	148,982 (19.6%)
3 (37.7 - 104%)	190,244 (25.9%)	8,463 (33.8%)	18,678 (21.9%)	1,003 (24.7%)	3,301,839 (23.7%)	198,707 (26.2%)
Recent immigration category (percentage of individuals in the area who are recent immigrants^k)						
1 (0.0 - 2.1%)	401,300 (54.7%)	8,271 (33.0%)	54,845 (64.3%)	2,002 (49.4%)	6,967,468 (50.0%)	409,571 (54.0%)
2 (2.1 - 4.7%)	146,772 (20.0%)	5,409 (21.6%)	14,834 (17.4%)	852 (21.0%)	2,858,064 (20.5%)	152,181 (20.1%)
3 (4.7 - 41.2%)	174,829 (23.8%)	11,018 (44.0%)	14,393 (16.9%)	1,133 (28.0%)	3,898,463 (28.0%)	185,847 (24.5%)
Visible minority quintile (percentage of individuals in the area self-identifying as a visible minority)						
1 (0.0 - 2.2%)	130,912 (17.8%)	1,716 (6.9%)	21,800 (25.5%)	555 (13.7%)	2,115,641 (15.2%)	132,628 (17.5%)
2 (2.2 - 7.5%)	137,826 (18.8%)	2,233 (8.9%)	19,869 (23.3%)	677 (16.7%)	2,255,245 (16.2%)	140,059 (18.5%)
3 (7.5 - 18.7%)	137,744 (18.8%)	3,201 (12.8%)	16,345 (19.1%)	792 (19.5%)	2,451,335 (17.6%)	140,945 (18.6%)
4 (18.7 - 43.5%)	153,503 (20.9%)	5,466 (21.8%)	13,581 (15.9%)	887 (21.9%)	3,023,752 (21.7%)	158,969 (21.0%)
5 (43.5 - 102%) ^l	167,893 (22.9%)	12,140 (48.5%)	13,280 (15.6%)	1,097 (27.1%)	3,940,245 (28.3%)	180,033 (23.7%)

^a “Rural” defined as located outside the commuting zone of a city with greater than 10,000 population.

^b Participants were counted if they had a diagnosis in the last 5 years.

^c Participants considered “immunocompromised” if they were HIV positive, or had an organ or bone marrow transplant, or another immunodeficient condition.

^d This category includes individuals with ischemic stroke or TIA in the last 20 years.

^e This category includes individuals with a diagnosis in the last 2 years.

^f Values of $\text{PM}_{2.5} > 12\mu\text{g}/\text{m}^3$ or $\text{NO}_2 > 53\text{ppb}$ yearly has been found to be associated with increased risk of other respiratory illnesses.⁸⁰ $\text{PM}_{2.5}$ and NO_2 values are provided at the postal code, not DA, level.

^g All variables in this category are area-level variables at the level of the Census Dissemination Area (DA).

^h Income quintile has variable cut-off values in each city or census area, to take cost of living into account. A DA being in quintile 1 means it is among the lowest 20% DAs in its city by income.

ⁱ The census counts for apartment buildings are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

^j 7.3% represents the 60th percentile.

^k 2.1% represents the 60th percentile.

^l Census counts for individuals are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

Table 2. Odds of ever being tested for SARS-CoV-2 and of COVID-19 diagnosis in fully-adjusted analyses, using three analytic approaches, in Ontario, Canada between March 1 and June 20, 2020.


Determinants	Tested for SARS-CoV-2	Diagnosed with COVID-19		
	Tested vs. not tested aOR (95% CI)	Test-positive vs. test-negative among all individuals tested (Pseudo-test-negative design) aOR (95% CI)	Test-positive vs. test-negative among symptomatic individuals only (True test-negative design) aOR (95% CI)	Test-positive vs. not test-positive (i.e., all negatives and all untested individuals) (Case-control design) aOR (95% CI) ^a
Sample size	14,695,579	758,691	89,408	14,695,579
Individual determinants				
Age groups (years) (ref: 0 – 4)				
5-19	1.15 (1.12, 1.18)	1.92 (1.66, 2.23)	2.93 (1.75, 4.91)	1.72 (1.48, 1.99)
20-34	4.13 (4.05, 4.22)	2.00 (1.75, 2.30)	4.02 (2.47, 6.55)	7.01 (6.12, 8.04)
35-49	4.13 (4.05, 4.21)	1.98 (1.72, 2.27)	4.20 (2.58, 6.84)	6.73 (5.87, 7.71)
50-64	4.20 (4.12, 4.29)	2.01 (1.75, 2.31)	5.46 (3.35, 8.90)	6.98 (6.08, 8.00)
65-74	3.03 (2.97, 3.10)	1.60 (1.38, 1.85)	5.05 (3.07, 8.31)	3.94 (3.41, 4.55)
75-84	3.00 (2.94, 3.07)	1.61 (1.38, 1.87)	5.37 (3.23, 8.93)	3.86 (3.33, 4.48)
≥85	5.57 (5.45, 5.70)	1.72 (1.48, 2.01)	5.95 (3.57, 9.92)	7.09 (6.08, 8.26)
Male sex	0.76 (0.76, 0.76)	1.26 (1.23, 1.30)	1.35 (1.26, 1.44)	1.00 (0.98, 1.03)
Living in rural/small town ^b	0.97 (0.96, 0.98)	0.81 (0.74, 0.88)	0.76 (0.65, 0.88)	0.76 (0.70, 0.83)
Public Health region (ref: Toronto)				
Central East	1.12 (1.10, 1.14)	0.40 (0.36, 0.45)	0.54 (0.42, 0.71)	0.44 (0.39, 0.50)
Central West	0.97 (0.96, 0.98)	0.61 (0.57, 0.65)	0.91 (0.78, 1.07)	0.58 (0.55, 0.62)
Durham	0.87 (0.86, 0.88)	0.95 (0.88, 1.02)	1.55 (1.24, 1.94)	0.81 (0.76, 0.87)
Eastern	1.06 (1.05, 1.08)	0.33 (0.29, 0.38)	0.39 (0.30, 0.51)	0.35 (0.31, 0.39)
North	1.19 (1.17, 1.21)	0.19 (0.16, 0.22)	0.30 (0.23, 0.39)	0.23 (0.19, 0.26)
Ottawa	0.97 (0.95, 0.99)	0.82 (0.75, 0.91)	1.06 (0.82, 1.37)	0.78 (0.70, 0.86)
Peel	0.98 (0.97, 0.99)	0.99 (0.95, 1.04)	0.75 (0.65, 0.87)	0.95 (0.91, 0.99)
South West	0.99 (0.98, 1.01)	0.61 (0.56, 0.66)	1.22 (1.01, 1.47)	0.60 (0.56, 0.65)
York	0.89 (0.88, 0.90)	0.88 (0.83, 0.93)	1.03 (0.88, 1.20)	0.77 (0.72, 0.81)
Underlying chronic health conditions				
Asthma	1.09 (1.09, 1.10)	0.86 (0.83, 0.89)	0.85 (0.78, 0.93)	0.93 (0.89, 0.96)
COPD	1.23 (1.21, 1.24)	0.89 (0.82, 0.96)	0.83 (0.70, 0.98)	1.05 (0.97, 1.13)
Hypertension	0.98 (0.98, 0.99)	1.12 (1.08, 1.16)	1.10 (1.00, 1.20)	1.13 (1.09, 1.18)
Diabetes	0.98 (0.97, 0.99)	1.26 (1.21, 1.31)	1.18 (1.07, 1.30)	1.19 (1.15, 1.24)
Congestive heart failure	1.26 (1.24, 1.28)	0.99 (0.92, 1.07)	0.92 (0.77, 1.11)	1.25 (1.16, 1.35)

Dementia or frailty score >15	2.12 (2.09, 2.15)	1.38 (1.29, 1.49)	1.69 (1.44, 1.98)	2.59 (2.41, 2.79)
Cancer ^c	1.13 (1.12, 1.15)	0.72 (0.66, 0.80)	0.87 (0.70, 1.09)	0.85 (0.78, 0.94)
Chronic kidney disease ^c	1.31 (1.29, 1.32)	0.86 (0.80, 0.93)	1.04 (0.88, 1.23)	1.16 (1.08, 1.24)
Immunocompromised ^d	1.30 (1.28, 1.33)	0.79 (0.70, 0.89)	0.84 (0.63, 1.10)	1.02 (0.91, 1.14)
Advanced liver disease	1.14 (1.11, 1.16)	0.78 (0.68, 0.90)	0.76 (0.54, 1.07)	0.87 (0.76, 1.00)
Ischemic heart disease	1.02 (1.01, 1.03)	0.88 (0.82, 0.95)	0.81 (0.68, 0.97)	0.90 (0.84, 0.97)
Ischemic stroke or TIA ^e	1.15 (1.13, 1.17)	1.05 (0.95, 1.17)	0.94 (0.73, 1.20)	1.18 (1.06, 1.31)
Schizophrenia ^f	1.24 (1.21, 1.27)	0.84 (0.73, 0.96)	1.28 (0.92, 1.77)	0.99 (0.86, 1.13)
Substance abuse ^f	1.17 (1.16, 1.19)	0.72 (0.65, 0.79)	0.52 (0.40, 0.68)	0.86 (0.78, 0.94)
Healthcare use				
Aggregated Diagnostic Group quintile (ref: 0 ADGs)				
2 (1-2 ADGs)	1.64 (1.62, 1.66)	0.78 (0.74, 0.84)	0.68 (0.58, 0.81)	1.24 (1.17, 1.32)
3 (3-4 ADGs)	2.07 (2.04, 2.10)	0.75 (0.70, 0.80)	0.57 (0.48, 0.68)	1.47 (1.37, 1.57)
4 (5-6 ADGs)	2.45 (2.41, 2.48)	0.74 (0.69, 0.79)	0.56 (0.47, 0.68)	1.69 (1.58, 1.82)
5 (7-27 ADGs)	3.11 (3.06, 3.15)	0.75 (0.69, 0.80)	0.52 (0.43, 0.63)	2.13 (1.98, 2.29)
Hospital admissions, past 3 years (ref: 0 admissions)				
1	0.99 (0.98, 1.00)	0.93 (0.89, 0.97)	0.88 (0.79, 0.98)	0.92 (0.88, 0.96)
2	1.16 (1.14, 1.17)	0.86 (0.79, 0.93)	0.80 (0.66, 0.97)	1.01 (0.94, 1.09)
≥3	1.75 (1.73, 1.78)	0.82 (0.76, 0.90)	1.04 (0.86, 1.26)	1.38 (1.27, 1.50)
Outpatient physician visits, past year (ref: 0 – 1 visits)				
2 – 4	1.08 (1.07, 1.09)	1.02 (0.98, 1.07)	1.07 (0.95, 1.19)	1.12 (1.08, 1.18)
5 – 8	1.11 (1.10, 1.12)	1.03 (0.98, 1.08)	1.01 (0.89, 1.15)	1.17 (1.11, 1.23)
9 – 14	1.17 (1.16, 1.18)	0.98 (0.93, 1.04)	1.04 (0.90, 1.20)	1.17 (1.10, 1.24)
≥15	1.36 (1.34, 1.37)	0.91 (0.85, 0.97)	0.88 (0.75, 1.03)	1.22 (1.14, 1.30)
Influenza vaccination (2019-2020 season)	1.08 (1.08, 1.09)	0.81 (0.78, 0.83)	0.86 (0.79, 0.93)	0.87 (0.84, 0.90)
Environmental determinants^g				
PM_{2.5} category (µg/m³) (ref: 2 – 6)				
6-7	0.97 (0.96, 0.98)	0.91 (0.84, 0.98)	0.81 (0.69, 0.96)	0.92 (0.85, 0.99)
7-8	0.91 (0.90, 0.92)	1.05 (0.95, 1.16)	0.99 (0.80, 1.22)	0.96 (0.87, 1.06)
8-9	0.90 (0.89, 0.92)	1.24 (1.11, 1.37)	1.15 (0.93, 1.43)	1.15 (1.04, 1.27)
≥10	0.89 (0.88, 0.91)	1.37 (1.22, 1.55)	1.49 (1.18, 1.90)	1.24 (1.10, 1.39)
NO₂ category (parts per billion) (ref: 0 – 6)				
6-8	0.96 (0.95, 0.96)	1.05 (1.00, 1.11)	1.05 (0.94, 1.16)	1.00 (0.95, 1.05)
≥8	0.93 (0.92, 0.95)	1.12 (1.05, 1.19)	1.08 (0.93, 1.26)	1.03 (0.97, 1.10)
Social determinants of health^h (area-level)				
Household income quintile (ref: 1st quintile,				

lowest income)				
2	1.03 (1.02, 1.04)	0.98 (0.93, 1.03)	0.95 (0.84, 1.08)	1.02 (0.97, 1.06)
3	1.09 (1.08, 1.10)	1.06 (0.99, 1.12)	0.96 (0.82, 1.12)	1.13 (1.07, 1.20)
4	1.11 (1.10, 1.13)	1.02 (0.95, 1.09)	0.95 (0.80, 1.12)	1.09 (1.02, 1.17)
5 (highest income)	1.12 (1.10, 1.14)	1.00 (0.92, 1.08)	1.22 (1.01, 1.47)	1.08 (1.00, 1.16)
Social assistance quintile^l (ref: 1st quintile)				
2	1.03 (1.02, 1.04)	1.11 (1.06, 1.16)	1.04 (0.93, 1.16)	1.12 (1.07, 1.18)
3	1.04 (1.04, 1.05)	1.19 (1.14, 1.26)	1.15 (1.02, 1.29)	1.22 (1.16, 1.28)
4	1.05 (1.04, 1.06)	1.20 (1.14, 1.27)	1.09 (0.96, 1.25)	1.22 (1.16, 1.30)
5	1.05 (1.04, 1.06)	1.36 (1.27, 1.45)	1.11 (0.95, 1.30)	1.38 (1.30, 1.47)
Limited educational attainment quintile^l (ref: 1st quintile)				
2	1.04 (1.03, 1.04)	1.11 (1.06, 1.16)	1.13 (1.01, 1.26)	1.15 (1.10, 1.20)
3	1.02 (1.02, 1.03)	1.23 (1.17, 1.29)	1.21 (1.08, 1.36)	1.26 (1.21, 1.33)
4	1.03 (1.02, 1.04)	1.33 (1.27, 1.40)	1.46 (1.29, 1.65)	1.36 (1.30, 1.43)
5	1.02 (1.01, 1.03)	1.49 (1.41, 1.58)	1.50 (1.31, 1.72)	1.52 (1.44, 1.60)
Uncoupled quintile^k (ref: 1st quintile)				
2	1.02 (1.01, 1.03)	0.96 (0.91, 1.01)	1.06 (0.96, 1.18)	0.97 (0.93, 1.02)
3	1.07 (1.06, 1.08)	0.96 (0.92, 1.01)	1.00 (0.88, 1.12)	1.01 (0.96, 1.06)
4	1.20 (1.18, 1.21)	0.98 (0.93, 1.04)	0.95 (0.83, 1.09)	1.14 (1.08, 1.21)
5	1.39 (1.38, 1.41)	1.09 (1.03, 1.17)	1.06 (0.91, 1.25)	1.46 (1.37, 1.56)
Household density quintile^l (ref: 1st quintile)				
2	1.02 (1.01, 1.02)	1.25 (1.19, 1.32)	1.24 (1.10, 1.40)	1.25 (1.19, 1.32)
3	1.04 (1.03, 1.05)	1.48 (1.40, 1.57)	1.36 (1.18, 1.57)	1.53 (1.45, 1.62)
4	1.03 (1.02, 1.04)	1.84 (1.74, 1.94)	1.82 (1.59, 2.09)	1.89 (1.79, 1.99)
5	0.98 (0.97, 0.99)	2.12 (1.99, 2.26)	1.74 (1.47, 2.05)	2.08 (1.95, 2.21)
Apartment building density category^m (ref: 1st category)				
2	1.03 (1.03, 1.04)	0.98 (0.94, 1.03)	1.00 (0.90, 1.10)	1.00 (0.96, 1.04)
3	1.02 (1.01, 1.03)	1.13 (1.08, 1.20)	1.08 (0.94, 1.24)	1.16 (1.10, 1.22)
Recent immigration categoryⁿ (ref: 1st category)				
2	1.00 (0.99, 1.00)	1.05 (1.00, 1.09)	1.12 (1.02, 1.23)	1.04 (1.00, 1.08)
3	0.94 (0.94, 0.95)	1.18 (1.12, 1.23)	1.31 (1.17, 1.47)	1.12 (1.07, 1.16)
Visible minority quintile^o (ref: 1st category)				
2	0.99 (0.98, 0.99)	0.94 (0.88, 1.01)	1.02 (0.90, 1.16)	0.94 (0.88, 1.00)
3	0.94 (0.93, 0.95)	0.94 (0.88, 1.01)	1.04 (0.91, 1.20)	0.89 (0.83, 0.96)
4	0.91 (0.90, 0.92)	1.03 (0.96, 1.11)	1.10 (0.94, 1.29)	0.94 (0.87, 1.01)
5	0.85 (0.84, 0.87)	1.22 (1.12, 1.33)	1.15 (0.95, 1.39)	1.03 (0.95, 1.12)


- ^a Fully-adjusted analyses contain as covariates all variables listed in this table.
- “Rural” defined as located outside the commuting zone of a city with greater than 10,000 population.
- ^b Participants were counted if they had a diagnosis in the last 5 years.
- ^c Participants considered “immunocompromised” if they were HIV positive, or had an organ or bone marrow transplant, or another immunodeficient condition.
- ^d This category includes individuals with ischemic stroke or TIA in the last 20 years.
- ^e This category includes individuals with a diagnosis in the last 2 years.
- ^f Values of $PM_{2.5} > 12\mu g/m^3$ or $NO_2 > 53ppb$ yearly has been found to be associated with increased risk of other respiratory illnesses.⁸⁰
- ^g All variables in this category are area-level variables at the level of the Census Dissemination Area.
- ^h 1st quintile represents 38.0 – 63.5% of individuals in the area receiving governmental transfer payments; 2nd quintile: 63.5 – 67.2% of individuals; 3rd quintile: 67.2 – 70.8% of individuals; 4th quintile: 70.8 - 75.3% of individuals; 5th quintile: 75.3 – 98.1% of individuals.
- ⁱ 1st quintile represents 0 – 4.1% of individuals 25-64 years old without diploma; 2nd quintile: 4.1 – 7.5% of individuals; 3rd quintile: 7.5 – 11.4% of individuals; 4th quintile: 11.4 – 17.1% of individuals; 5th quintile: 17.1 – 94.3% of individuals.
- ^j 1st quintile represents 11.2 – 33.7% individuals uncoupled; 2nd quintile: 33.7 – 38.4% individuals; 3rd quintile: 38.5 – 43.6% individuals; 4th quintile: 43.6 – 51.0% individuals; 5th quintile: 51.0 – 94.6% individuals.
- ^k 1st quintile represents 0-2.1 persons/dwelling; 2nd quintile: 2.2 – 2.4 persons/dwelling; 3rd quintile: 2.5 – 2.6 persons/dwelling; 4th quintile: 2.7 – 3 persons/dwelling; 5th quintile: 3.1 – 5.7 persons/dwelling.
- ^l 1st category represents 0 – 7.3% of buildings in the area being apartment buildings; 2nd category: 7.4 – 37.7% of buildings; 3rd category: 37.7 – 100% of buildings.
- ^m 1st category represents 0 – 2.1% of individuals in DA being recent immigrants; 2nd category: 2.1 – 4.7% of individuals; 3rd category: 4.7 – 41.2% of individuals.
- ⁿ 1st quintile represents 0 – 2.2% of individuals in the area self-identifying as a visible minority; 2nd quintile: 2.2 – 7.5% of individuals; 3rd quintile: 7.5 – 18.7% of individuals; 4th quintile: 18.7 – 43.5% of individuals; 5th quintile: 43.5 – 100% of individuals.

Figure 1. Diagram of inclusion and exclusion criteria and resulting analytic datasets.




Individuals were excluded if they had a listed age >105 years, had a listed postal code outside of Ontario, or had no record of contact with the healthcare system in the past 8 years (since March 2012).

Figure 2. Unadjusted, sex/age adjusted, and fully adjusted association between social determinants and SARS-CoV-2 testing (panel A) and COVID-19 diagnosis (panel B), using the case-control design, in Ontario (March 1 to June 20, 2020).



Forest plots show the odds of being tested for SARS-CoV-2, compared to the reference group (1st quintile or 1st category). In all cases, the first quintile/category represents the lowest quintile of values for the variable at the dissemination area (DA)-level. For example, the lowest quintile of household income represents individuals living in the lowest 20% of DAs by income quintile. Age/sex-adjusted models are shown in Table 2. Fully-adjusted models control for all variables listed in Table 2, including (but not limited to) all variables shown in this figure; effect estimates and 95% CIs for all models shown here can be found in eTable 2.



Forest plots show the odds of being tested for SARS-CoV-2, compared to the reference group (1st quintile or 1st category). In all cases, the first quintile/ category represents the lowest quintile of values for the variable at the dissemination (DA)-level. For example, the lowest quintile of DA-level income represents individuals living in the lowest 20% of DAs by income quintile. Fully-adjusted models are shown in the rightmost column of Table 2 and control for all variables listed in Table 2, including (but not limited to) all variables shown in this figure. Effect estimates and 95% CIs for all models shown here can be found in eTable 5.